Interactions between calcium and alpha-synuclein in neurodegeneration

Biomolecules

Volumn 4, Issue 3, 2014, Pages 795-811

  Rcom H’cheo Gauthier, Alex ^a   Goodwin, Jacob ^a   Pountney, Dean L ^a  

^a GRIFFITH UNIVERSITY   (Australia)

Author keywords

Alpha synuclein; Calcium; Multiple system atrophy; Neurodegeneration; Oxidative stress; Parkinson s disease

Indexed keywords

ALPHA SYNUCLEIN; CALBINDIN; CALCIUM ION; PESTICIDE; REACTIVE OXYGEN METABOLITE; TRIMETHADIONE; CALCIUM; PROTEIN BINDING;

AGE; CALCIUM CELL LEVEL; CYTOTOXICITY; ENVIRONMENTAL FACTOR; EXOSOME; HUMAN; MOLECULAR INTERACTION; NONHUMAN; OLIGOMERIZATION; OXIDATIVE STRESS; PARKINSON DISEASE; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REVIEW; SHY DRAGER SYNDROME; ANIMAL; CHEMISTRY; INTRACELLULAR SPACE; METABOLISM; NEURODEGENERATIVE DISEASES; PATHOLOGY; PROTEIN MULTIMERIZATION;

ALPHA-SYNUCLEIN; ANIMALS; CALCIUM; HUMANS; INTRACELLULAR SPACE; NEURODEGENERATIVE DISEASES; PROTEIN BINDING; PROTEIN MULTIMERIZATION;

EID: 84933045609     PISSN: None     EISSN: 2218273X     Source Type: Journal    
DOI: 10.3390/biom4030795     Document Type: Review

References (100)

1. Goedert, M.; Spillantini, M.G.; del Tredici, K.; Braak, H. 100 years of Lewy pathology. Nat. Rev. Neurol. 2013, 9, 13-24.
2. Eschbach, J.; Danzer, K.M. α-Synuclein in Parkinson’s disease: Pathogenic function and translation into animal models. Neurodegener. Dis. 2014, 14, 1-17.
3. Radford, R.; Wong, M.B.; Pountney, D.L. Neurodegenerative aspects of multiple system atrophy. In Handbook of Neurotoxicity; Kostrzewa, R.M., Ed.; Springer: New York, NY, USA, 2014; pp. 2157-2180.
4. Krüger, R.; Kuhn, W.; Müller, T.; Woitalla, D.; Graeber, M.; Kösel, S.; Przuntek, H.; Epplen, J.T.; Schöls, L.; Riess, O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson’s disease. Nat. Genet. 1998, 18, 106-108.
5. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; et al. Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Science 1997, 276, 2045-2047.
6. Zarranz, J.J.; Alegre, J.; Gómez-Esteban, J.C.; Lezcano, E.; Ros, R.; Ampuero, I.; Vidal, L.; Hoenicka, J.; Rodriguez, O.; Atarés, B.; et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 2004, 55, 164-173.
7. Lesage, S.; Anheim, M.; Letournel, F.; Bousset, L.; Honore, A.; Rozas, N.; Pieri, L.; Madiona, K.; Durr, A.; Melki, R.; et al. G51D α-Synuclein mutation causes a novel parkinsonian-pyramidal syndrome. Ann. Neurol. 2013, 73, 459-471.
8. Proukakis, C.; Dudzik, C.G.; Brier, T.; MacKay, D.S.; Cooper, J.M.; Millhauser, G.L.; Houlden, H.; Schapira, A.H. A novel α-synuclein missense mutation in Parkinson disease. Neurology 2013, 80, 1062-1064.
9. Kanda, S.; Bishop, J.F.; Eglitis, M.A.; Yang, Y.; Mouradian, M.M. Enhanced viability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 2000, 97, 279-284.
10. Narhi, L.; Wood, S.J.; Steavenson, S.; Jiang, Y.; Wu, G.M.; Anafi, D.; Kaufman, S.A.; Martin, F.; Sitney, K.; Denis, P.; et al. Both familial Parkinson’s disease mutations accelerate alpha-synuclein aggregation. J. Biol. Chem. 1999, 274, 9843-9846.
11. Khalaf, O.; Fauvet, B.; Oueslati, A.; Dikiy, I.; Mahul-Mellier, A.L.; Ruggeri, F.S.; Mbefo, M.; Vercruysse, F.; Dietler, G.; Lee, S.J.; et al. The H50Q mutation enhances α-synuclein aggregation, secretion and toxicity. J. Biol. Chem. 2014, doi: 10.1074/jbc.M114.553297.
12. Ibáñez, P.; Bonnet, A.M.; Débarges, B.; Lohmann, E.; Tison, F.; Pollak, P.; Agid, Y.; Dürr, A.; Brice, A. Causal relation between alpha-synuclein gene duplication and familial Parkinson’s disease. Lancet 2004, 364, 1169-1171.
13. Singleton, A.B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague, S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; et al. alpha-Synuclein locus triplication causes Parkinson’s disease. Science 2003, doi: 10.1126/science.1090278.
14. Tanner, C.M.; Kamel, F.; Ross, W.; Hoppin, J.A.; Goldman, S.M.; Korell, M.; Marras, C.; Bhudhikanok, G.S.; Kasten, M.; Chade, A.R.; et al. Rotenone, paraquat, and Parkinson’s disease. Environ. Health Perspect. 2011, 119, 866-872.
15. Wang, X.; Su, B.; Liu, W.; He, X.; Gao, Y.; Castellani, R.J.; Perry, G.; Smith, M.A.; Zhu, X. DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: Implications for Parkinson’s disease. Ageing Cell. 2011, 10, 807-823.
16. Hernán, M.A.; Takkouche, B.; Caamaño-Isorna, F.; Gestal-Otero, J.J. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson’s disease. Ann. Neurol. 2002, 52, 276-284.
17. Spillantini, M.G.; Schmidt, M.L.; Lee, V.M.; Trojanowski, J.Q.; Jakes, R.; Goedert, M. Alpha-synuclein in Lewy bodies. Nature 1997, 388, 839-840.
18. Al-Chalabi, A.; Dürr, A.; Wood, N.W.; Parkinson, M.H.; Camuzat, A.; Hulot, J.S.; Morrison, K.E.; Renton, A.; Sussmuth, S.D.; Landwehrmeyer, B.G.; et al. Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One 2009, 4, e7114.
19. Hanna, P.A.; Jankovic, J.; Kirkpatrick, J.B. Multiple system atrophy: The putative causative role of environmental toxins. Arch. Neurol. 1999, 56, 90-94.
20. Vidal, J.S.; Vidailhet, M.; Elbaz, A.; Derkinderen, P.; Tzourio, C.; Alpérovitch, A. Risk factors of multiple system atrophy: A case-control study in French patients. Mov. Disord. 2008, 23, 797-803.
21. Iwai, A.; Masliah, E.; Yoshimoto, M.; Ge, N.; Fianagan, L.; Rohan de Silva, H.A.; Kittei, A.; Saitoh, T. The precursor protein of non-aβ component of Alzheimer’s disease amyloid is a presynaptic protein of the central nervous system. Neuron 1995, 14, 467-475.
22. Maroteaux, L.; Campanelli, J.T.; Scheller, R.H. Synuclein: A neuron-specific protein localized to the nucleus and presynaptic nerve terminal. J. Neurosci. 1998, 8, 2804-2815.
23. Clayton, D.F.; George, J.M. Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 1999, 58, 120-129.
24. Burré, J.; Sharma, M.; Tsetsenis, T.; Buchman, V.; Etherton, M.R.; Südhof, T.C. Alpha-synuclein promotes SNARE-complex assembly in vivo and in vitro. Science 2010, 329, 1663-1667.
25. 2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J. Biol. Chem. 2001, 276, 22680-22684.
26. Giasson, B.I.; Murray, I.V.; Trojanowski, J.Q.; Lee, V.M. A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J. Biol. Chem. 2001, 276, 2380-2386.
27. Eliezer, D.; Kutluay, E.; Bussell, R., Jr.; Browne, G. Conformational properties of alpha-synuclein in its free and lipid-associated states. J. Mol. Biol. 2001, 307, 1061-1073.
28. Davidson, W.S.; Jonas, A.; Clayton, D.F.; George, J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 1998, 273, 9443-9449.
29. Wietek, J.; Haralampiev, I.; Amoussouvi, A.; Herrmann, A.; Stöckl, M. Membrane bound α-synuclein is fully embedded in the lipid bilayer while segments with higher flexibility remain. FEBS Lett. 2013, 587, 2572-2577.
30. Wood, S.J.; Wypych, J.; Steavenson, S.; Lousis, J-C.; Citron, M.; Biere, A.L. α-Synuclein fibrillogenesis is nucleation dependent: Implications for the pathogenesis of Parkinson’s disease. J. Biol. Chem. 1999, 274, 19509-19512.
31. Zibaee, S.; Jakes, R.; Fraser, G.; Serpell, L.C.; Crowther, R.A.; Goedert, M. Sequence determinants for amyloid fibrillogenesis of human alpha-synuclein. J. Mol. Biol. 2007, 374, 454-464.
32. Narayanan, V.; Scarlata, S. Membrane binding and self-association of alpha-synucleins. Biochemistry 2001, 40, 9927-9934.
33. Lokappa, S.B.; Suk, J.E.; Balasubramanian, A.; Samanta, S.; Situ, A.J.; Ulmer, T.S. Sequence and membrane determinants of the random coil-helix transition of α-synuclein. J. Mol. Biol. 2014, 426, 2130-2144.
34. McLean, P.J.; Kawamata, H.; Ribich, S.; Hyman, T. Membrane association and protein conformation of α-synuclein in intact neurons. J. Biol. Chem. 2000, 275, 8812-8816.
35. Chen, R.H.; Wislet-Gendebien, S.; Samuel, F.; Visanji, N.P.; Zhang, G.; Marsilio, D.; Langman, T.; Fraser, P.E.; Tandon, A. α-Synuclein membrane association is regulated by the Rab3a recycling machinery and presynaptic activity. J. Biol. Chem. 2013, 288, 7438-7449.
36. Mak, S.R.; McCormack, A.L.; Langston, J.W.; Kordower, J.H.; di Monte, D.A. Decreased α-synuclein expression in the ageing mouse substantia nigra. Exp. Neurobiol. 2009, 220, 359-365.
37. Grundemann, J.; Schlaudraff, F.; Haeckel, O.; Liss, B. Elevated α-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in Idiopathic Parkinson’s disease. Nucleic Acids Res. 2008, 36, e38.
38. Outeiro, T.F.; Putcha, P.; Tetzlaff, J.E.; Spoelgen, R.; Koker, M.; Carvalho, F.; Hyman, B.T.; McLean, P.J. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One 2008, 3, e1867.
39. Esteves, A.R.; Arduíno, D.M.; Silva, D.F.; Oliveira, C.R.; Cardoso, S.M. Mitochondrial dysfunction: The Road to alpha-synuclein oligomerization in PD. Parkinsons Dis. 2011, doi: 10.4061/2011/693761.
40. Kalia, L.V.; Kalia, S.K.; McLean, P.J.; Lozano, A.M.; Lang, A.E. α-Synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol. 2013, 73, 155-169.
41. Yasuda, T.; Nakata, Y.; Mochizuki, H. α-Synuclein and neuronal cell death. Mol. Neurobiol. 2013, 47, 466-483.
42. 2+-induced mitochondrial dysfunction. J. Biol. Chem. 2014, doi: 10.1074/jbc.M113.545749.
43. Danzer, K.M.; Haasen, D.; Karow, A.R.; Moussaud, S.; habeck, M.; Giese, A.; Kretzschmar, H.; Hengerer, B.; Kostka, M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 2007, 27, 9220-9232.
44. Bartels, T.; Choi, J.C.; Selkoe, D.J. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature 2011, 477, 107-111.
45. Wang, W.; Perovic, W.; Chittuluru, J.; Kaganovich, A.; Nguyen, L.T.T.; Liao, J.; Auclair, J.R.; Johnson, D.; Landeru, D.; Simorellis, A.K.; et al. A soluble α-synuclein construct forms a dynamic tetramer. Proc. Natl. Acad. Sci. USA 2011, 108, 17797-17802.
46. Smith, W.W.; Margolis, R.L.; Li, X.; Troncoso, J.C.; Lee, M.K.; Dawson, V.L.; Dawson, T.M.; Iwatsubo, T.; Ross, C.A. Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in SH-SY5Y cells. J. Neurosci. 2005, 25, 5544-5552.
47. Lu, Y.; Prudent, M.; Fauvet, B.; Lashuel, H.A.; Girault, H.H. Phosphorylation of α-Synuclein at Y125 and S129 alters its metal binding properties: Implications for understanding the role of α-synuclein in the pathogenesis of Parkinson’s disease and related disorders. ACS Chem. Neurosci. 2011, 2, 667-675.
48. Liu, L.L.; Franz, K.J. Phosphorylation of an alpha-synuclein peptide fragment enhances metal binding. J. Am. Chem. Soc. 2005, 127, 9662-9663.
49. Anderson, J.P.; Walker, D.E.; Goldstein, J.M.; de Laat, R.; Banducci, K.; Caccavello, R.J.; Barbour, R.; Huang, J.; Kling, K.; Lee, M.; et al. Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease. J. Biol. Chem. 2006, 281, 29739-29752.
50. Uversky, V.N.; Yamin, G.; Munishkina, L.A.; Karymov, M.A.; Millett, I.S.; Doniach, S.; Lyubchenko, Y.L.; Fink, A.L. Effects of nitration on the structure and aggregation of alpha-synuclein. Mol. Brain Res. 2005, 134, 84-102.
51. Chavarría, C.; Souza, J.M. Oxidation and nitration of α-synuclein and their implications in neurodegenerative diseases. Arch. Biochem. Biophys. 2013, 533, 25-32.
52. Glaser, C.B.; Yamin, G.; Uversky, V.N.; Fink, A.L. Methionine oxidation, alpha-synuclein and Parkinson’s disease. Biochim. Biophys. Acta 2005, 1703, 157-169.
53. Uversky, V.N.; Yamin, G.; Souillac, P.O.; Goers, J.; Glaser, C.B.; Fink, A.L. Methionine oxidation inhibits fibrillation of human alpha-synuclein in vitro. FEBS Lett. 2002, 517, 239-244.
54. Feany, M.B.; Bender, W.W. A Drosophila model of Parkinson’s disease. Nature 2000, 404, 394-398.
55. Kaul, S.; Anantharam, V.; Kanthasamy, A.; Kanthasamy, A.G. Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death. Brain Res. Mol. Brain Res. 2005, 139, 137-152.
56. Pham, C.L.; Cappai, R. The interplay between lipids and dopamine on α-synuclein oligomerization and membrane binding. Biosci. Rep. 2013, 33, e00074.
57. Lee, H.J.; Bae, E.J.; Lee, S.J. Extracellular α-synuclein-A novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 2014, 10, 92-98.
58. Alvarez-Erviti, L.; Seow, Y.; Schapira, A.H.; Gardiner, C.; Sargent, I.L.; Wood, M.J.; Cooper, J.M. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol. Dis. 2011, 42, 360-367.
59. Danzer, K.M.; Kranich, L.R.; Ruf, W.P.; Cagsal-Getkin, O.; Winslow, A.R.; Zhu, L.; Vanderburg, C.R.; McLean, P.J. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 2012, doi: 10.1186/1750-1326-7-42.
60. Kovacs, G.G.; Breydo, L.; Green, R.; Kis, V.; Puska, G.; Lőrincz, P.; Perju-Dumbrava, L.; Giera, R.; Pirker, W.; Lutz, M.; et al. Intracellular processing of disease-associated α-synuclein in the human brain suggests prion-like cell-to-cell spread. Neurobiol. Dis. 2014, doi: 10.1016/j.nbd.2014.05.020.
61. Chang, C.; Lang, H.; Geng, N.; Wang, J.; Li, N.; Wang, X. Exosomes of BV-2 cells induced by alpha-synuclein: Important mediator of neurodegeneration in PD. Neurosci. Lett. 2013, 26, 190-195.
62. Kordower, J.H.; Chu, Y.; Hauser, R.A.; Freeman, T.B.; Olanow, C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson’s disease. Nat. Med. 2008, 14, 504-506.
63. Li, J.Y.; Englund, E.; Holton, J.L.; Soulet, D.; Hagell, P.; Lees, A.J.; Lashley, T.; Quinn, N.P.; Rehncrona, S.; Bjorklund, A.; et al. Lewy bodies in grafted neurons in subjects with Parkinson’s disease suggest host-to-graft disease propagation. Nat. Med. 2008, 14, 501-503.
64. Sims-Robertson, C.; Hur, J.; Hayes, J.M.; Dauch, J.R.; Keller, P.J.; Brooks, S.V.; Feldman, E.L. The role of oxidative stress in nervous system aging. PLoS One 2013, 8, e68011.
65. Castro, R.; Suarez, E.; Kraiselburd, E.; Isidro, A.; Paz, J.; Ferder, L.; Ayala-Torres, S. Aging increases mitochondrial DNA damage and oxidative stress in liver of rhesus monkeys. Exp. Gerentol. 2012, 47, 29-37.
66. Quilty, M.C.; King, A.E.; Gai, W.P.; Pountney, D.L.; West, A.K.; Vickers, J.C.; Dickson, T.C. Alpha-synuclein is upregulated in neurons in response to chronic oxidative stress and is associated with neuroprotection. Exp. Neurol. 2006, 199, 249-256.
67. Surmeier, D.J.; Schumacker, P.T. Calcium, bioenergetics, and neuronal vulnerability in Parkinson’s disease. J. Biol. Chem. 2013, 288, 10736-10741.
68. Fairless, R.; Williams, S.K.; Diem, R. Dysfunction of neuronal calcium signalling in neuroinflammation and neurodegeneration. Cell Tissue Res. 2013, doi: 10.1007/s00441-013-1758-8.
69. Lowe, R.; Pountney, D.L.; Jensen, P.H.; Gai, W.P.; Voelcker, N.H. Calcium(II) selectively induces alpha-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci. 2004, 13, 3245-3252.
70. Brini, M.; Calì, T.; Ottolini, D.; Carafoli, E. Neuronal calcium signaling: Function and dysfunction. Cell. Mol. Life Sci. 2014, doi: 10.1007/s00018-013-1550-7.
71. Michaelis, M.L.; Bigelow, D.J.; Schöneich, C.; Williams, T.D.; Ramonda, L.; Yin, D.; Hühmer, A.F.; Yao, Y.; Gao, J.; Squier, T.C. Decreased plasma membrane calcium transport activity in aging brain. Life Sci. 1996, 59, 405-412.
72. Duckles, S.P.; Tsai, H.; Buchholz, J.N. Evidence for decline in intracellular calcium buffering in adrenergic nerves of aged rats. Life Sci. 1996, 58, 2029-2035.
73. 2+ buffer to a multifunctional protein implicated in many biological processes. Front. Neuroanat. 2014, doi: 10.3389/fnana.2014.00003.
74. Perier, C.; Vila, M. Mitochondrial biology and Parkinson’s disease. Cold Spring Harb. Prospect. Med. 2012, doi: 10.1101/cshperspect.a009332.
75. Bu, J.; Sathyendra, V.; Nagykery, N.; Geula, C. Age-related changes in calbindin-D28k, calretinin, and parvalbumin-immunoreactive neurons in the human cerebral cortex. Exp. Neurol. 2003, 182, 220-231.
76. German, D.C.; Manaye, K.F.; Sonsalla, P.K.; Brooks, B.A. Midbrain dopaminergic cell loss in Parkinson’s disease and MPTP-induced Parkinsonism: Sparing of calbindin-D 28K containing cells. Ann. NY Acad. Sci. 1992, 648, 42-62.
77. Tsuboi, K.; Kimber, T.A.; Shults, C.W. Calretinin-containing axon and neurons are resistant to intrastriatal 6-hydroxydopamine. Brain Res. 2000, 866, 55-64.
78. Kim, B.G.; Shin, D.H.; Jeon, G.S.; Seo, J.H.; Kim, Y.W.; Jeon, B.S.; Cho, S.S. Relative sparing of calretinin containin neurons in the substantia nigra of 6-OHDA treated rat Parkinsonian model. Brain Res. 2000, 7, 162-165.
79. Yamada, T.; McGeer, P.L.; Bainbridge, K.G.; McGeer, E.C. Relative sparing in Parkinson’s disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 1990, 526, 303-307.
80. Nath, S.; Goodwin, J.; Engelborghs, Y.; Pountney, D.L. Raised calcium promotes α-synuclein aggregate formation. Mol. Cell. Neurosci. 2011, 46, 516-526.
81. Follett, J.; Darlow, B.; Wong, M.B.; Goodwin, J.; Pountney, D.L. Potassium depolarization and raised calcium induces α-synuclein aggregates. Neurotox. Res. 2013, 23, 378-392.
82. Kopecky, B.J.; Liang, R.; Bao, J. T-type calcium channel blockers as neuroprotective agents. Eur. J. Physiol. 2014, 466, 757-765.
83. Chan, S.C.; Guzman, J.N.; Ilijic, E.; Mecer, J.N.; Rick, C.; Tkatch, T.; Meredith, G.E.; Surmeier, D.J. "Rejuvenation" protects neurons in mouse models of Parkinson’s disease. Nature 2007, 447, 1081-1089.
84. Gasper, P.; Ben Jelloun, N.; Febvret, A. Sparing of the dopaminergic neurons containing calbindin-D28k and the loss of dopaminergic mesocortical projections in weaver mice. Neuroscience 1994, 61, 293-305.
85. Weetman, J.; Wong, M.B.; Sharry, S.; Rcom-H’cheo-Gauthier, A.; Gai, W.P.; Meedeniya, A.; Pountney, D.L. Increased SUMO-1 expression in the unilateral rotenone-lesioned mouse model of Parkinson’s disease. Neurosci. Lett. 2013, 544, 119-124.
86. Rcom-H’cheo-Gauthier, A.; Meedeniya, A.; Pountney, D.L. School of Medical Science, Griffith University, Gold Coast, Australia. Unpublished work, 2014.
87. Goodwin, J.; Nath, S.; Engelborghs, Y.; Pountney, D.L. Raised calcium and oxidative stress cooperatively promote alpha-synuclein aggregate formation. Neurochem. Int. 2013, 62, 703-711.
88. 2+ signaling in human neuroblastoma (SH-SY5Y) cells. J. Neurochem. 2009, 111, 1192-1201.
89. Melachroinou, K.; Xilouri, M.; Emmanouilidou, E.; Masgrau, R.; Papazafiri, P.; Stefanis, L.; Vekrellis, K. Deregulation of calcium homeostasis mediates secreted alpha-synuclein-induced neurotoxicity. Neurobiol. Aging 2013, 34, 2853-2865.
90. Reznichenko, L.; Cheng, Q.; Nizar, K.; Gratiy, S.L.; Saisan, P.A.; Rockenstein, E.M.; González, T.; Patrick, C.; Spencer, B.; Desplats, P.; et al. In vivo alterations in calcium buffering capacity in transgenic mouse model of synucleinopathy. J. Neurosci. 2012, 32, 9992-9998.
91. Cali, T.; Ottolini, D.; Negro, A.; Brini, M. alpha-Synuclein controls mitochondrial calcium homeostasis by enhancing endoplasmic reticulum-mitochondria interactions. J. Biol. Chem. 2012, 287, 17914-17929.
92. Dryanovski, D.I.; Guzman, J.N.; Xie, Z.; Galteri, D.J.; Volpicelli-Daley, L.A.; Lee, V.M.; Miller, R.J.; Scumacker, P.T.; Surmeier, D.J. Calcium entry and alpha-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons. J. Neurosci. 2013, 33, 10154-10164.
93. 2+ levels to alpha-synuclein toxicity in Parkinson’s disease models. Cell Death Differ. 2013, 20, 465-477.
94. Parihar, M.S.; Parihar, A.; Fujita, M.; Hashimoto, M.; Ghafourifar, P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cell. Mol. Life Sci. 2008, 65, 1272-1284.
95. Hashimoto, M.; Hsu, L.J.; Rockenstein, E.; Takenouchi, T.; Mallory, M.; Masliah, E. α-Synuclein protects against oxidative stress via inactivation of the c-Jun N-terminal kinase stress-signalling pathway in neuronal cells. J. Biol. Chem. 2002, 277, 11465-11472.
96. Stefanova, N.; Reindl, M.; Neumann, M.; Haass, C.; Poewe, W.; Kahle, P.J.; Wenning, G.K. Oxidative stress in transgenic mice with oligodendroglial α-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am. J. Pathol. 2005, 166, 869-876.
97. Nath, S.; Meuvis, J.; Hendrix, J.; Carl, S.A.; Engelborghs, Y. Early aggregation steps in alpha-synuclein as measured by FCS and FRET: Evidence for a contagious conformational change. Biophys. J. 2010, 98, 1302-1311.
98. Krishnan, S.; Chi, E.Y.; Wood, S.J.; Kendrick, B.S.; Li, C.; Garzon-Rodrigues, W.; Wypych, J.; Randolph, T.W.; Narhi, L.O.; Biere, A.L.; et al. Oxidative dimer formation is the critical rate-limiting step for Parkinson’s disease α-synuclein fibrillogenesis. Biochemistry 2003, 42, 829-837.
99. Goldberg, J.A.; Guzman, J.N.; Estep, C.M.; Ilijic, E.; Kondapalli, J.; Sanchez-Padilla, J.; Surmerier, D.J. Calcium entry induces mitochondrial oxidant stress in vagal neurons at risk in Parkinson’s disease. Nat. Neurosci. 2012, 15, 1414-1421.
100. Schapira, A.H.; Olanow, C.W.; Greenamyre, J.T.; Bezard, E. Slowing of neurodegeneration in Parkinson’s disease and Huntington’s disease: Future therapeutic perspectives. Lancet 2014, doi: 10.1016/S0140-6736(14)61010-2.